Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664417 · ClinicalTrials.gov registry record · Phase 1
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 375
- Enrollment target
NCT00664417: Completed Phase 1 study, sponsored by Sanofi.
NCT00664417 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 375 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (525% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00664417, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 375 participants
- Enrollment target
Study Summary
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated. The present study is part of this endeavor. It is primarily a formulation/dose-finding study with a secondary aim at generating safety and immunogenicity data for the final formulation for the development of a pre-pandemic vaccine.
Interventions
- BIOLOGICAL Monovalent subvirion H5N1 influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
What the finished NCT00664417 record still lists
NCT00664417 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (525% higher).
The record links to 0 conditions, and to 1 intervention - of which Monovalent subvirion H5N1 influenza vaccine is the first listed.
NCT00664417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00664417 about?
NCT00664417 is a clinical study titled "Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine". Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated. The present study is part of this endeavor. It is primarily a formulation/dose-finding ...
What is the current status of trial NCT00664417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 375 participants. The study started on 2008-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00664417?
The interventions under investigation include: Monovalent subvirion H5N1 influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00664417?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00664417's enrollment target sits among peer trials
375 84th of 2000 higher than 1,916 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia